目的：研究后Tenon囊下注射20mg曲安奈德(TA)治疗黄斑水肿后的眼压变化及眼压升高的影响因素。 方法：黄斑水肿患者46例46眼，病因为糖尿病性视网膜病变16例，年龄相关性黄斑变性13例，视网膜静脉栓塞11例，后葡萄膜炎6例，均行后Tenon囊下注射20mg TA。注射前测量眼压，并于注射后2wk;1,2,3,4,5,6mo随访观察眼压变化。 结果：患者46例术后2wk;1,2,3,4,5,6mo平均眼压较术前均有升高。术后3mo时，平均眼压达最高值（19.22±6.86）mmHg，有17例（37%）患者IOP>21mmHg。术后2wk；1，2，3，4，5mo眼压与术前比较,差别有统计学意义（t值分别为3.747，5.836，5.982，5.866，4.202，3.246，均P<0.05），术后6mo眼压与术前比较，差别无统计学意义(t=1446，P>0.05)。年轻、基础眼压高是后Tenon囊下注射曲安奈德后继发性眼压升高的危险因素（χ²值分别为5599,10.323，均P<0.05），而性别、病因与后Tenon囊下注射曲安奈德后继发性眼压升高没有相关性（χ²值分别为0.022,0.050，均P>0.05）。 结论：后Tenon囊下注射20mg曲安奈德，引起眼压升高较为常见，在注射后3mo时眼压升高最为明显，注射后6mo时回落至基础眼压水平。年轻、基础眼压高是继发性眼压升高的危险因素。注射后进行最短为期6mo的眼压随访是非常必要的，尤其是对于年轻患者及基础眼压高的患者。

AIM:To investigate the changes of intraocular pressure (IOP) and associated factors of IOP elevation after posterior sub-Tenon’s capsule (PST) injection with triamcinolone acetonide (TA) for macular edema. METHODS:The study included 46 cases(46 eyes) who received PST injections of 20mg TA to treat macular edema with diabetic retinopathy (n=16),age-related macular degeneration (n=13), retinal vein occlusion (n=11),and posterior uveitis (n=6). IOP measurements were performed on the day of injection, and 2 weeks，1 month，2, 3, 4, 5 and 6 months later. RESULTS:The mean IOP of all eyes showed a gradual increase after the injection, peaked at 3 months (19.22±6.86mmHg), and then decreased gradually until reaching a minimum at 6 months. Of the 46 eyes, 17(37%) showed an IOP above 21 mmHg at 3 months post-injection. Compared with the pre-injection, the mean IOP increased significantly at 2 weeks，1 month，2，3，4，5 months（t value were 3.747, 5.836, 5.982, 5.866, 4.202, 3.246 respectively, all P<0.05）, however, there was no significant difference between the pre-injection and the 6 months post-injection (t=1.446,P>0.05) . And IOP elevation significantly correlated with younger age（χ²=5599，P<005）and higher baseline IOP（χ²=10.323，P<005）, but not with gender（χ2=0.022，P>0.05）or disease（χ^{2=0.050，P>0.05）. CONCLUSION:E1evation of IOP after PST injection with TA is not rare and the peak level usually occurs at 3 months post-injection, and then the IOP decreases gradually to approach the baseline level until 6 months post-injection. Younger age and higher baseline IOP are identified as risk factors. Our findings indicate that careful assessment of IOP during a follow-up at least 6 months is necessary，especially in those who are younger or with higher baseline IOP.}